RU2016150656A - Новые комбинации для антигенной терапии - Google Patents
Новые комбинации для антигенной терапии Download PDFInfo
- Publication number
- RU2016150656A RU2016150656A RU2016150656A RU2016150656A RU2016150656A RU 2016150656 A RU2016150656 A RU 2016150656A RU 2016150656 A RU2016150656 A RU 2016150656A RU 2016150656 A RU2016150656 A RU 2016150656A RU 2016150656 A RU2016150656 A RU 2016150656A
- Authority
- RU
- Russia
- Prior art keywords
- paragraphs
- composition
- autoantigen
- beta
- patient
- Prior art date
Links
- 230000000890 antigenic effect Effects 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 8
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 7
- 102000008214 Glutamate decarboxylase Human genes 0.000 claims 6
- 108091022930 Glutamate decarboxylase Proteins 0.000 claims 6
- 229930003316 Vitamin D Natural products 0.000 claims 6
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 6
- 239000002245 particle Substances 0.000 claims 6
- 235000019166 vitamin D Nutrition 0.000 claims 6
- 239000011710 vitamin D Substances 0.000 claims 6
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 6
- 229940046008 vitamin d Drugs 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 102000004877 Insulin Human genes 0.000 claims 4
- 108090001061 Insulin Proteins 0.000 claims 4
- 229940125396 insulin Drugs 0.000 claims 4
- WVYADZUPLLSGPU-UHFFFAOYSA-N salsalate Chemical compound OC(=O)C1=CC=CC=C1OC(=O)C1=CC=CC=C1O WVYADZUPLLSGPU-UHFFFAOYSA-N 0.000 claims 4
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 3
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 102000010792 Chromogranin A Human genes 0.000 claims 2
- 108010038447 Chromogranin A Proteins 0.000 claims 2
- 229940122204 Cyclooxygenase inhibitor Drugs 0.000 claims 2
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 claims 2
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 claims 2
- 102100036255 Glucose-6-phosphatase 2 Human genes 0.000 claims 2
- 101000930907 Homo sapiens Glucose-6-phosphatase 2 Proteins 0.000 claims 2
- 108010076181 Proinsulin Proteins 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000003197 catalytic effect Effects 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 206010022498 insulinoma Diseases 0.000 claims 2
- 208000021255 pancreatic insulinoma Diseases 0.000 claims 2
- 108010066381 preproinsulin Proteins 0.000 claims 2
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims 2
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 claims 2
- 239000002452 tumor necrosis factor alpha inhibitor Substances 0.000 claims 2
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 102100035857 Glutamate decarboxylase 2 Human genes 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 108090000144 Human Proteins Proteins 0.000 claims 1
- 102000003839 Human Proteins Human genes 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 229960003697 abatacept Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 229960002964 adalimumab Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940037003 alum Drugs 0.000 claims 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 229960003428 dexibuprofen Drugs 0.000 claims 1
- HEFNNWSXXWATRW-JTQLQIEISA-N dexibuprofen Chemical compound CC(C)CC1=CC=C([C@H](C)C(O)=O)C=C1 HEFNNWSXXWATRW-JTQLQIEISA-N 0.000 claims 1
- 229960002783 dexketoprofen Drugs 0.000 claims 1
- DKYWVDODHFEZIM-NSHDSACASA-N dexketoprofen Chemical compound OC(=O)[C@@H](C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-NSHDSACASA-N 0.000 claims 1
- 229960000616 diflunisal Drugs 0.000 claims 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 claims 1
- 229940105576 disalcid Drugs 0.000 claims 1
- 229960001850 droxicam Drugs 0.000 claims 1
- OEHFRZLKGRKFAS-UHFFFAOYSA-N droxicam Chemical compound C12=CC=CC=C2S(=O)(=O)N(C)C(C2=O)=C1OC(=O)N2C1=CC=CC=N1 OEHFRZLKGRKFAS-UHFFFAOYSA-N 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 229960004945 etoricoxib Drugs 0.000 claims 1
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 1
- 229960004369 flufenamic acid Drugs 0.000 claims 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 108010024780 glutamate decarboxylase 2 Proteins 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 229960001743 golimumab Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 229960000598 infliximab Drugs 0.000 claims 1
- 229950002252 isoxicam Drugs 0.000 claims 1
- YYUAYBYLJSNDCX-UHFFFAOYSA-N isoxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC=1C=C(C)ON=1 YYUAYBYLJSNDCX-UHFFFAOYSA-N 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 229960002202 lornoxicam Drugs 0.000 claims 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 claims 1
- 229960002373 loxoprofen Drugs 0.000 claims 1
- YMBXTVYHTMGZDW-UHFFFAOYSA-N loxoprofen Chemical compound C1=CC(C(C(O)=O)C)=CC=C1CC1C(=O)CCC1 YMBXTVYHTMGZDW-UHFFFAOYSA-N 0.000 claims 1
- 229960000994 lumiracoxib Drugs 0.000 claims 1
- KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 229960003803 meclofenamic acid Drugs 0.000 claims 1
- 229960003464 mefenamic acid Drugs 0.000 claims 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960000965 nimesulide Drugs 0.000 claims 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 claims 1
- 229960002739 oxaprozin Drugs 0.000 claims 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 claims 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims 1
- 229960004662 parecoxib Drugs 0.000 claims 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- -1 phenoprofen Chemical compound 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 229960004889 salicylic acid Drugs 0.000 claims 1
- 229960000953 salsalate Drugs 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229960000894 sulindac Drugs 0.000 claims 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 1
- 229960002871 tenoxicam Drugs 0.000 claims 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 claims 1
- 229960001017 tolmetin Drugs 0.000 claims 1
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 229960002004 valdecoxib Drugs 0.000 claims 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01005—Acetolactate decarboxylase (4.1.1.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (22)
1. Способ профилактики и/или лечения аутоиммунного заболевания, включающий введение пациенту композиции, где указанная композиция содержит по меньшей мере один аутоантиген бета-клеток, путем внутрилимфатической инъекции или инъекции непосредственно в лимфатический узел.
2. Способ по п.1, где аутоантиген бета-клеток выбран из группы, состоящей из декарбоксилазы глутаминовой кислоты (GAD), антигена-2 инсулиномы, ZnT8, островково-специфического белка каталитической субъединицы глюкозо-6-фосфата (IGRP), хромогранина А, инсулина, В-цепи инсулина, препроинсулина или проинсулина.
3. Способ по п.1, где аутоантиген бета-клеток вводят в количестве 1-15 мкг, более предпочтительно, в диапазоне 2-10 мкг, и наиболее предпочтительно, в диапазоне 2-5 мкг на одну инъекцию и используемый аутоантиген.
4. Способ по пп.1, 2 или 3, включающий введение композиции, содержащей аутоантиген бета-клеток, по меньшей мере 2 раза, более предпочтительно, по меньшей мере 3 раза, и наиболее предпочтительно, по меньшей мере 4 раза, при этом каждое введение осуществляют по меньшей мере 14 дней друг от друга, более предпочтительно, по меньшей мере 30 дней друг от друга.
5. Способ по любому из пп. 1-4, дополнительно включающий введение пациенту ингибитора циклооксигеназы.
6. Способ по п.5, где ингибитор циклооксигеназы выбран из группы, состоящей из ибупрофена, дексибупрофена, напроксена, фенопрофена, кетопрофена, декскетопрофена, флурбипрофена, оксапрозина, локсопрофена, индометацина, толметина, сулиндака, этодолака, кеторолака, диклофенака, ацеклофенака, набуметона, ацетилсалициловой кислоты, дифлунизала (долобида), салициловой кислоты, салсалата (дисалцида), пироксикама, мелоксикама, теноксикама, дроксикама, лорноксикама, изоксикама, мефенамовой кислоты, меклофенамовой кислоты, флуфенамовой кислоты, толфенамовой кислоты, целекоксиба, рофекоксиба, вальдекоксиба, парекоксиба, лумиракоксиба, эторикоксиба и нимесулида.
7. Способ по любому из пп. 1-6, дополнительно включающий введение пациенту соединения CTLA4, такого как абатацепт.
8. Способ по любому из пп. 1-7, дополнительно включающий введение пациенту ингибитора TNF-альфа.
9. Способ по п.8, где ингибитор TNF-альфа выбран из группы, состоящей из адалимумаба, сертолизумаба, этанерцепта, голимумаба и инфликсимаба.
10. Способ по любому из пп. 1-9, дополнительно включающий введение пациенту витамина D, аналогов витамин D, ингибиторов тирозинкиназы, гамма-аминомасляной кислоты или аналога гамма-аминомасляной кислоты и/или воздействие на пациента УФB-излучения.
11. Способ по п.10, где введение витамина D и/или аналогов витамина D и/или воздействие УФB-излучения осуществляют в течение от 7 до 90 дней до введения пациенту композиции, содержащейпо меньшей мере один аутоантиген бета-клеток.
12. Способ по п.10 или 11, где способ включает введение витамина D и/или аналогов витамина D в количестве 7000-70000 международных единиц в неделю в течение 3-48 месяцев.
13. Способ по любому из пп. 11-12, включающий введение пациенту композиции по любому из пп. 51-58.
14. Способ по любому из пп. 1-13, где аутоиммунное заболевание представляет собой диабет 1 типа или аутоиммунный диабет.
15. Композиция, содержащая множество частиц, каждая из которых содержит иммобилизованные на поверхности по меньшей мере один первый и по меньшей мере один второй антиген, где первый антиген представляет собой аутоантиген бета-клеток, а второй антиген является либо толерогеном, либо аутоантигеном бета-клеток, при этом композиция дополнительно необязательно включает фармацевтически приемлемые адъюванты, эксципиенты, растворители и/или буферные агенты.
16. Композиция по п.15, где все аутоантигены бета-клеток выбраны из группы, состоящей из декарбоксилазы глутаминовой кислоты (GAD), антигена-2 инсулиномы, ZnT8, островково-специфического белка каталитической субъединицы глюкозо-6-фосфата (IGRP), хромогранина А, инсулина, В-цепи инсулина, препроинсулина или проинсулина.
17. Композиция по п.15 или 16, где по меньшей мере один аутоантиген бета-клеток представляет собой декарбоксилазу глутаминовой кислоты (GAD).
18. Композиция по любому из пп. 15-17, где по меньшей мере одним аутоантигеном бета-клеток является GAD-65.
19. Композиция по любому из пп. 15-18, где второй антиген представляет собой толероген.
20. Композиция по п.19, где толероген представляет собой нативный белок человека, такой как IL-10, сывороточный альбумин или гемоглобин человека, или гамма-аминомасляную кислоту.
21. Композиция по любому из пп. 15-20, где частица представляет собой частицу гидроксида алюминия (alum), липосому, наночастицу, частичку золота или биоразлагаемую частицу.
22. Композиция по любому из пп. 15-21, где каждая частица имеет иммобилизованные на поверхности 2, 3, 4, 5, 6, 7, 8, 9 или 10 различных антигенов, выбранных из группы, которая включает толерогены и аутоантигены бета-клеток.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1450678-6 | 2014-06-04 | ||
| SE1450678 | 2014-06-04 | ||
| SE1451315 | 2014-11-04 | ||
| SE1451315-4 | 2014-11-04 | ||
| PCT/SE2015/050651 WO2015187087A2 (en) | 2014-06-04 | 2015-06-04 | Novel combinations for antigen based therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019129803A Division RU2019129803A (ru) | 2014-06-04 | 2015-06-04 | Новые комбинации для антигенной терапии |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016150656A true RU2016150656A (ru) | 2018-07-10 |
| RU2016150656A3 RU2016150656A3 (ru) | 2019-01-25 |
| RU2702632C2 RU2702632C2 (ru) | 2019-10-09 |
Family
ID=54767532
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016150656A RU2702632C2 (ru) | 2014-06-04 | 2015-06-04 | Новые комбинации для антигенной терапии |
| RU2019129803A RU2019129803A (ru) | 2014-06-04 | 2015-06-04 | Новые комбинации для антигенной терапии |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019129803A RU2019129803A (ru) | 2014-06-04 | 2015-06-04 | Новые комбинации для антигенной терапии |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20170196949A1 (ru) |
| EP (2) | EP3760224A3 (ru) |
| JP (2) | JP6686007B2 (ru) |
| CN (2) | CN106535926B (ru) |
| AU (3) | AU2015268960B2 (ru) |
| CA (2) | CA3210184A1 (ru) |
| CY (1) | CY1123160T1 (ru) |
| DK (1) | DK3151853T3 (ru) |
| ES (1) | ES2807787T3 (ru) |
| HU (1) | HUE051151T2 (ru) |
| IL (3) | IL300130B1 (ru) |
| LT (1) | LT3151853T (ru) |
| PL (1) | PL3151853T3 (ru) |
| PT (1) | PT3151853T (ru) |
| RS (1) | RS60581B1 (ru) |
| RU (2) | RU2702632C2 (ru) |
| SI (1) | SI3151853T1 (ru) |
| WO (1) | WO2015187087A2 (ru) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018133139A1 (zh) | 2017-01-21 | 2018-07-26 | 宁波知明生物科技有限公司 | 芍药苷-6'-o-苯磺酸酯在治疗干燥综合征的应用 |
| EP4300102A3 (en) | 2017-09-08 | 2024-01-24 | Diamyd Medical AB | Improved immunotherapy |
| US20210077587A1 (en) * | 2017-09-08 | 2021-03-18 | Diamyd Medical Ab | Genotype stratification in diabetes treatment and prevention |
| US20200360496A1 (en) * | 2018-02-05 | 2020-11-19 | Diamyd Medical Ab | Novel composition and use thereof |
| WO2019173533A1 (en) * | 2018-03-07 | 2019-09-12 | Athenex HK Innovative Limited | Compositions and methods for treating hyperproliferative skin disorders |
| US10500217B2 (en) | 2018-04-30 | 2019-12-10 | Leslie Ray Matthews, M.D., Llc | Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases |
| WO2020210798A1 (en) * | 2019-04-12 | 2020-10-15 | Loma Linda University | Methods for treatment of niemann-pick disease type c |
| WO2022155188A1 (en) * | 2021-01-13 | 2022-07-21 | University Of Maryland, College Park | Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto |
| TW202315884A (zh) * | 2021-06-17 | 2023-04-16 | 英商法姆製藥責任有限公司 | 使用衍生自患者之抗原特異性調節ｔ細胞的個體化細胞療法 |
| WO2023066881A1 (en) * | 2021-10-18 | 2023-04-27 | Astrazeneca Ab | Inhibition of map3k15 for treating and preventing diabetes |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5674978A (en) * | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
| US5853723A (en) * | 1995-09-21 | 1998-12-29 | University Of Utah Research Foundation | Targeting of peg antibody conjugates to islet cells |
| SE9503379D0 (sv) * | 1995-09-29 | 1995-09-29 | Synectics Medical Ab | A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD |
| US6884785B2 (en) * | 1999-06-17 | 2005-04-26 | The Scripps Research Institute | Compositions and methods for the treatment or prevention of autoimmune diabetes |
| CA2435758C (en) * | 2001-11-21 | 2016-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Polynucleotide therapy against autoantigens for treating insulin dependent diabetes mellitus |
| US20050152914A1 (en) * | 2003-06-13 | 2005-07-14 | Diamyd, Inc. | Formulation of antigen |
| AU2005213449A1 (en) * | 2004-02-04 | 2005-08-25 | The La Jolla Institute For Allergy And Immunology | Anti-CD3 and antigen-specific immunotherapy to treat autoimmunity |
| EP1755631A2 (en) * | 2004-03-03 | 2007-02-28 | Diamyd Medical AB | Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes |
| CN101365494A (zh) * | 2005-10-05 | 2009-02-11 | 贝希尔治疗学股份有限公司 | 治疗自身免疫性疾病的组合物和方法 |
| JP5694668B2 (ja) * | 2006-12-29 | 2015-04-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 自己免疫疾患の診断上および治療上の標的ならびにその用途 |
| KR20100022022A (ko) * | 2007-04-24 | 2010-02-26 | 다이아미드 쎄라퓨틱스 아베 | 자가면역 질환 및 암을 치료하기 위한 의약 및 방법 |
| EP2630967A1 (en) * | 2007-10-12 | 2013-08-28 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| EP2219669A4 (en) * | 2007-12-19 | 2011-03-09 | Mivac Dev Aktiebolag | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND ALLERGIC DISEASES |
| EP3753410A3 (en) * | 2010-09-28 | 2021-04-28 | The Regents Of The University Of California | Combinations comprising gaba agonists in treatment of hyperglycemia |
| WO2012062697A1 (en) * | 2010-11-08 | 2012-05-18 | Novartis Ag | Combination therapy for type 1 diabetes |
| US8735359B2 (en) * | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
-
2015
- 2015-06-04 DK DK15802815.9T patent/DK3151853T3/da active
- 2015-06-04 ES ES15802815T patent/ES2807787T3/es active Active
- 2015-06-04 JP JP2017516633A patent/JP6686007B2/ja active Active
- 2015-06-04 LT LTEP15802815.9T patent/LT3151853T/lt unknown
- 2015-06-04 AU AU2015268960A patent/AU2015268960B2/en active Active
- 2015-06-04 EP EP20172919.1A patent/EP3760224A3/en active Pending
- 2015-06-04 CN CN201580040912.4A patent/CN106535926B/zh active Active
- 2015-06-04 PL PL15802815T patent/PL3151853T3/pl unknown
- 2015-06-04 SI SI201531269T patent/SI3151853T1/sl unknown
- 2015-06-04 RU RU2016150656A patent/RU2702632C2/ru active
- 2015-06-04 WO PCT/SE2015/050651 patent/WO2015187087A2/en active Application Filing
- 2015-06-04 HU HUE15802815A patent/HUE051151T2/hu unknown
- 2015-06-04 PT PT158028159T patent/PT3151853T/pt unknown
- 2015-06-04 US US15/315,557 patent/US20170196949A1/en not_active Abandoned
- 2015-06-04 IL IL300130A patent/IL300130B1/en unknown
- 2015-06-04 EP EP15802815.9A patent/EP3151853B1/en active Active
- 2015-06-04 CN CN202210193065.7A patent/CN114504639A/zh active Pending
- 2015-06-04 RS RS20200789A patent/RS60581B1/sr unknown
- 2015-06-04 CA CA3210184A patent/CA3210184A1/en active Pending
- 2015-06-04 RU RU2019129803A patent/RU2019129803A/ru unknown
- 2015-06-04 CA CA2950893A patent/CA2950893C/en active Active
-
2016
- 2016-11-28 IL IL249250A patent/IL249250B/en active IP Right Grant
-
2020
- 2020-03-12 IL IL273265A patent/IL273265B2/en unknown
- 2020-04-01 JP JP2020066176A patent/JP2020125300A/ja active Pending
- 2020-05-15 AU AU2020203169A patent/AU2020203169B2/en active Active
- 2020-07-28 CY CY20201100694T patent/CY1123160T1/el unknown
-
2021
- 2021-08-26 US US17/458,018 patent/US20220000995A1/en active Pending
-
2022
- 2022-03-23 AU AU2022202003A patent/AU2022202003A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016150656A (ru) | Новые комбинации для антигенной терапии | |
| JP2017516870A5 (ru) | ||
| Wang et al. | The mTOR pathway in the control of protein synthesis | |
| ES2869155T3 (es) | Péptidos inmunogénicos para su uso en la prevención y/o tratamiento de enfermedades infecciosas, enfermedades autoinmunitarias, respuestas inmunitarias a alofactores, enfermedades alérgicas, tumores, rechazo de injerto y respuestas inmunitarias contra vectores virales usados para terapia génica o vacunación génica | |
| Sakata et al. | The spleen as an optimal site for islet transplantation and a source of mesenchymal stem cells | |
| RU2018136760A (ru) | НОВЫЕ ИММУНОГЕННЫЕ CD1d-СВЯЗЫВАЮЩИЕ ПЕПТИДЫ | |
| JP2018023397A5 (ru) | ||
| Zhang et al. | PDX-1: a promising therapeutic target to reverse diabetes | |
| Wang et al. | A forskolin-conjugated insulin analog targeting endogenous glucose-transporter for glucose-responsive insulin delivery | |
| Pujol-Autonell et al. | Immunotherapy with tolerogenic dendritic cells alone or in combination with rapamycin does not reverse diabetes in NOD mice | |
| Monneaux et al. | Peptide-based immunotherapy of systemic lupus erythematosus | |
| HRP20201030T1 (hr) | Dekarboksilaza glutaminske kiseline (gad) za uporabu za liječenje autoimune bolesti | |
| Smetnev et al. | The role of peptide hormones (adiponectin, leptin, insulin) in the pathogenesis of atherosclerosis | |
| Willis et al. | Polyarthritis in the rat: effects of tolerance and sensitization to the bacterial extract OM-89 with a possible mode of action | |
| WO2017116569A1 (en) | Methods for treating diabetes | |
| CN114588249A (zh) | 诱导Goodpasture综合征粘膜耐受的口服药物 | |
| Broadfoot | Inflammation and degeneration-an integrative approach. | |
| AR115881A1 (es) | Inmunoterapia con péptidos restringidos a b*07 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| EA202190572A1 (ru) | Иммунотерапия раковых заболеваний рестриктированными по a*01 пептидами и комбинациями пептидов и относящиеся к ней способы | |
| US20160317573A1 (en) | Prophylaxis and therapy for age related illnesses | |
| Hospers et al. | Construction of a triple modified p53 containing DNA vaccine to enhance processing and presentation of the p53 antigen | |
| Gupta | Vaccines for Type 1 Diabetes | |
| Lew et al. | Autoimmunity to Both Proinsulin and IGRP | |
| ISLETS | ISL ETS | |
| Akhmetchenko et al. | Efficiency of tactivin and tocopherol for 2, 4-dichlorophenoxyacetic acid amine salt hepatotoxicity correction |